Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02662296
Title Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

non-Hodgkin lymphoma

CLL/SLL

Therapies

Idelalisib

Ibrutinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.